Scinai Immunotherapeutics Eyes Debt-Equity Swap

Scinai Immunotherapeutics (SCNI) has released an update.

Scinai Immunotherapeutics Ltd. has received an updated Letter of Intent from the European Investment Bank indicating a potential conversion of a significant loan into equity, which could not only resolve the company’s shareholders’ deficit but also ensure compliance with Nasdaq’s Equity Requirement. The proposed terms suggest converting approximately $28 million of debt into preferred shares, leaving a nominal loan balance, and cancelling variable remuneration rights, positively impacting the company’s financial standing. This move is subject to approval and would involve amending the company’s articles of association.

For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.